CLDN1 and metabolic dysfunction-associated steatohepatitis: In summary, our study provided evidence that a larger dose of UDCA is effective for treating NASH, and the proposed mechanism might be that it could partially restore gut microbiota dysbiosis and increase the expression of Claudin-1 and ZO-1 in the intestine.